AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15610261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dilution hemodiafiltration (HDF) with Nephros OLpur MD 190 hemodiafilter
Number of subjects: 10
Study 15610261 — intervention group
Group type: COMPARATOR
Intervention: Post-dilution hemodiafiltration (HDF) with conventional synthetic high-flux dialyzer
Number of subjects: 10
Study 12175402 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lignocaine infiltrated into the periprostatic nerve plexus bilaterally
Number of subjects: 86
Study 12175402 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mL of 2% lignocaine gel rectally
Number of subjects: 86
Study 12175402 — intervention group
Group type: COMPARATOR
Intervention: Plain gel rectally
Number of subjects: 86
Study 12175402 — intervention group
Group type: COMPARATOR
Intervention: Saline injection into the periprostatic nerve plexus
Number of subjects: 86
Study 10206568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (n = 19) with 12 weekly sessions
Number of subjects: 55
Study 10206568 — intervention group
Group type: COMPARATOR
Intervention: Rheumatological treatment alone (Control group)
Number of subjects: 55
Study 8582345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonucleotide (CAC)5 fingerprinting
Number of subjects: 0
Study 8582345 — intervention group
Group type: COMPARATOR
Intervention: Probes 33.15 and 33.6
Number of subjects: 0
Study 2240631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) anesthesia
Number of subjects: 100
Study 2240631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N2O)
Number of subjects: 100
Study 2240631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (N2O and no N2O)
Number of subjects: 100
Study 4601668 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (1,3 bis (2 chloroethyl) 1 nitrosourea)
Number of subjects: 44
Study 31678410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry Collaborative Care
Number of subjects: 1004
Study 31678410 — intervention group
Group type: COMPARATOR
Intervention: Telepsychiatry Enhanced Referral
Number of subjects: 1004
Study 31678410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1004
Study 31518615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal airway (OPA) with mask PPV
Number of subjects: 137
Study 31518615 — intervention group
Group type: COMPARATOR
Intervention: Face mask alone (control group)
Number of subjects: 137
Study 28394933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg+40 mg)
Number of subjects: 38
Study 28394933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg twice)
Number of subjects: 38
Study 28394933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) and Ezetimibe (10 mg) twice
Number of subjects: 38
Study 28394933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25734777 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling between each lunge in sessions 1 and 2, and 5 times in 7 days between sessions 1 and 2.
Number of subjects: 31
Study 25734777 — intervention group
Group type: COMPARATOR
Intervention: Control group did not foam roll at all.
Number of subjects: 31
Study 25734777 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling intervention group.
Number of subjects: 31
Study 22961467 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Enhanced Discharge Planning Program intervention
Number of subjects: 0
Study 22961467 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 22026929 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 245
Study 22026929 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 245
Study 19531260 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 3307
Study 17012773 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (10 months, 3 sessions/week)
Number of subjects: 320
Study 17012773 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent antioxidant supplementation (Biofrutas)
Number of subjects: 320
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: RER (Respiratory Exchange Ratio) warm-up
Number of subjects: 12
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR (Heart Rate Reserve) warm-up
Number of subjects: 12
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: HP (Hydrocollator Pads) warm-up
Number of subjects: 12
Study 15320663 — intervention group
Group type: COMPARATOR
Intervention: Control (no warm-up)
Number of subjects: 12
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: RER warm-up
Number of subjects: 12
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR warm-up
Number of subjects: 12
Study 15320663 — intervention group
Group type: EXPERIMENTAL
Intervention: HP warm-up
Number of subjects: 12
Study 11094106 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of rizatriptan for three attacks and placebo for one attack
Number of subjects: 473
Study 12206033 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice
Number of subjects: 0
Study 12206033 — intervention group
Group type: COMPARATOR
Intervention: Crest Gum Care Toothpaste
Number of subjects: 0
Study 12206033 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular Toothpaste
Number of subjects: 0
Study 8382710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and maprotiline treatment
Number of subjects: 0
Study 3786347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.347 g/kg ethanol
Number of subjects: 18
Study 3786347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.695 g/kg ethanol
Number of subjects: 18
Study 3786347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30467781 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 30467781 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 30467781 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 27391539 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotrue with etafilcon A
Number of subjects: 568
Study 27391539 — intervention group
Group type: EXPERIMENTAL
Intervention: PureMoist with galyfilcon A
Number of subjects: 568
Study 27391539 — intervention group
Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec with senofilcon A
Number of subjects: 568
Study 27391539 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotrue, PureMoist, or RevitaLens OcuTec with galyfilcon A
Number of subjects: 568
Study 27391539 — intervention group
Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec with galyfilcon A
Number of subjects: 568
Study 25528621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 0
Study 25528621 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 0
Study 25528621 — intervention group
Group type: COMPARATOR
Intervention: Both groups (DHS and PFN)
Number of subjects: 0
Study 22459434 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Acupuncture (DA)
Number of subjects: 0
Study 22459434 — intervention group
Group type: COMPARATOR
Intervention: Superficial Acupuncture (SA)
Number of subjects: 0
Study 22459434 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 0
Study 20967307 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched abutment connections at subcrestal locations
Number of subjects: 282
Study 20967307 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight abutment connections
Number of subjects: 282
Study 20967307 — intervention group
Group type: COMPARATOR
Intervention: Straight abutment connections at supra- and subcrestal locations
Number of subjects: 282
Study 20967307 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of platform-switched concept
Number of subjects: 282
Study 18658056 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonotactic probability
Number of subjects: 19
Study 16401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg
Number of subjects: 150
Study 16401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 150
Study 16401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg
Number of subjects: 150
Study 16401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg and 50 mg
Number of subjects: 150
Study 12090608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy manipulation in Study 1
Number of subjects: 187
Study 12090608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy assessment in Study 2
Number of subjects: 187
Study 10612406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dk hydrogel lenses (etafilcon A, Dk = 28) worn for up to 7 days and 6 nights
Number of subjects: 0
Study 10612406 — intervention group
Group type: COMPARATOR
Intervention: High-Dk hydrogel lenses (lotrafilcon A, Dk = 140) worn for up to 30 days and nights
Number of subjects: 0
Study 8588059 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 2
Study 8588059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 1957744 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilatation with a 2 mm balloon followed by a definitive size balloon for angioplasty (group 1)
Number of subjects: 54
Study 1957744 — intervention group
Group type: COMPARATOR
Intervention: No predilatation, only definitive size balloon for angioplasty (group 2)
Number of subjects: 54
Study 6814355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of cefuroxime
Number of subjects: 358
Study 6814355 — intervention group
Group type: COMPARATOR
Intervention: 4.8 x 10(6) U of aqueous procaine penicillin G intramuscularly and 1.0 g of probenecid
Number of subjects: 358
Study 30894365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441
Study 30894365 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441
Study 30894365 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional risk factors (pulse, triglycerides, albumin excretion rate)
Number of subjects: 1441
Study 28507269 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose argatroban (100 μg/kg bolus followed by infusion of 1 μg/kg per minute for 48 hours)
Number of subjects: 90
Study 28507269 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐tPA+high‐dose argatroban (100 μg/kg bolus followed by infusion of 3 μg/kg per minute for 48 hours)
Number of subjects: 90
Study 28507269 — intervention group
Group type: COMPARATOR
Intervention: r‐tPA alone
Number of subjects: 90
Study 28507269 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose or high‐dose argatroban
Number of subjects: 90
Study 28507269 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐tPA+low‐dose argatroban
Number of subjects: 90
Study 28507269 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐tPA+high‐dose argatroban
Number of subjects: 90
Study 25891339 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-lidocaine combination
Number of subjects: 14
Study 25891339 — intervention group
Group type: COMPARATOR
Intervention: Alkalinized lidocaine
Number of subjects: 14
Study 23324690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 93
Study 23324690 — intervention group
Group type: EXPERIMENTAL
Intervention: biofeedback assisted relaxation and stretching (BFB)
Number of subjects: 93
Study 23324690 — intervention group
Group type: EXPERIMENTAL
Intervention: balance exercises on a wobble board (BAL)
Number of subjects: 93
Study 23324690 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 93
Study 21729717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 58
Study 21729717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion suppression during an upsetting movie
Number of subjects: 66
Study 18778742 — intervention group
Group type: COMPARATOR
Intervention: Natural reaction to the upsetting movie
Number of subjects: 66
Study 18778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically depressed BED group
Number of subjects: 66
Study 18778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 66
Study 17426848 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithalamine (pineal gland peptide preparation)
Number of subjects: 0
Study 17426848 — intervention group
Group type: COMPARATOR
Intervention: Control group (same basic therapy)
Number of subjects: 0
Study 14727106 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (ACTH (4-9) analogue)
Number of subjects: 150
Study 14727106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11158450 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 11
Study 11158450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 9246979 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) > or = 25 at age 40
Number of subjects: 503
Study 9246979 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 503
Study 9246979 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of contraceptive pills
Number of subjects: 503
Study 9246979 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen substitution
Number of subjects: 503
Study 7906700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure integrated with urge coping skills training (CET)
Number of subjects: 40
Study 7906700 — intervention group
Group type: COMPARATOR
Intervention: Contrast condition (CC)
Number of subjects: 40
Study 3773577 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual station‐designed schedules
Number of subjects: 4
Study 3773577 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight shifts
Number of subjects: 4
Study 3773577 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular schedule with unlimited requests for changes
Number of subjects: 4
Study 3773577 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 29577915 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training intervention
Number of subjects: 576
Study 27026043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) + Interferon β-1a (30 μg/week)
Number of subjects: 95
Study 27026043 — intervention group
Group type: COMPARATOR
Intervention: Control group (Interferon β-1a 30 μg/week)
Number of subjects: 95
Study 26603251 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling treatment
Number of subjects: 58
Study 26603251 — intervention group
Group type: COMPARATOR
Intervention: Callus debridement
Number of subjects: 58
Study 24325987 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 40 mg with lidocaine 1% (total volume 1 ml)
Number of subjects: 40
Study 24325987 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% alone (total volume 1 ml)
Number of subjects: 40
Study 19967342 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + 2 nucleoside reverse transcriptase inhibitors (2NRTI) once daily
Number of subjects: 0
Study 19967342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV) + 2NRTI once daily
Number of subjects: 0
Study 19967342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV) + 2NRTI twice daily
Number of subjects: 0
Study 18341724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 145
Study 18341724 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 145
Study 15726658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg IV after EVL followed by 40 mg oral for 9 days)
Number of subjects: 44
Study 15726658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV and oral)
Number of subjects: 44
Study 12657843 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management (1 ml/kg/h during surgery, total 9.5 ml/kg/h)
Number of subjects: 22
Study 12657843 — intervention group
Group type: COMPARATOR
Intervention: Aggressive fluid management (8 ml/kg/h during surgery)
Number of subjects: 22
Study 12657843 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management
Number of subjects: 22
Study 11013273 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (200 mg/m² intravenous daily 15 to 30 minutes before irradiation)
Number of subjects: 0
Study 11013273 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (1.8 to 2.0 Gy to doses of 50 to 70 Gy)
Number of subjects: 0
Study 1531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mononine (monoclonal antibody‐purified factor IX)
Number of subjects: 10
Study 1531035 — intervention group
Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 10
Study 6384617 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinfar (40 mg daily)
Number of subjects: 48
Study 6384617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoptin (240 mg daily)
Number of subjects: 48
Study 6384617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30747547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (800 μg every 4 hours, three doses)
Number of subjects: 200
Study 30747547 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 μg every 4 hours, three doses)
Number of subjects: 200
Study 30747547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 200
Study 30747547 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 200
Study 30403271 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP block + IV PCA tramadol
Number of subjects: 50
Study 30403271 — intervention group
Group type: COMPARATOR
Intervention: GAN block + IV PCA tramadol
Number of subjects: 50
Study 26091686 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp with 30 mL of 270 mg I/mL contrast material and iterative reconstruction (IR)
Number of subjects: 82
Study 26091686 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp with 60 mL of 370 mg I/mL contrast material and filtered back projection
Number of subjects: 82
Study 24771775 — intervention group
Group type: EXPERIMENTAL
Intervention: S/RP treatment with endoscopic detection of calculus
Number of subjects: 30
Study 24771775 — intervention group
Group type: COMPARATOR
Intervention: S/RP with tactile determination of calculus using an 11/12 explorer
Number of subjects: 30
Study 22777367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 169
Study 22777367 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension with pelvic floor muscle training
Number of subjects: 169
Study 22777367 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension without pelvic floor muscle training
Number of subjects: 169
Study 22777367 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS
Number of subjects: 169
Study 20832439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal breakfast
Number of subjects: 123
Study 20832439 — intervention group
Group type: COMPARATOR
Intervention: Muffin breakfast
Number of subjects: 123
Study 18205099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL) 40 mg
Number of subjects: 30
Study 18205099 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril (TRAN) 4 mg
Number of subjects: 30
Study 17249272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Maruyama Index surgery
Number of subjects: 0
Study 17249272 — intervention group
Group type: EXPERIMENTAL
Intervention: Maruyama Index of Unresected Disease (MI) <5
Number of subjects: 0
Study 17249272 — intervention group
Group type: EXPERIMENTAL
Intervention: Maruyama Index (MI)
Number of subjects: 0
Study 12010583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/d, 3 g EPA+DHA)
Number of subjects: 55
Study 12010583 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo, 6 g/d)
Number of subjects: 55
Study 9536924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lactate (40 mumol min-1 kg-1)
Number of subjects: 10
Study 9536924 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 9536924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lactate
Number of subjects: 10
Study 8587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0
Study 8587284 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (Control)
Number of subjects: 0
Study 8587284 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P. system
Number of subjects: 0
Study 2571265 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (120 micrograms)
Number of subjects: 3
Study 31603121 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga + standard antiemetic therapy
Number of subjects: 100
Study 31603121 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy alone
Number of subjects: 100
Study 29037148 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECEDE-based education intervention (9 sessions)
Number of subjects: 0
Study 29037148 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care
Number of subjects: 0
Study 25616941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - 10 minutes of inflow occlusion followed by 10 minutes of reperfusion before liver transection
Number of subjects: 106
Study 25616941 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic preconditioning (APC) - sevoflurane administration for 20 minutes before liver transection
Number of subjects: 106
Study 25616941 — intervention group
Group type: COMPARATOR
Intervention: Intermittent clamping (INT) - no preconditioning
Number of subjects: 106
Study 23095710 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg•kg(‐1)
Number of subjects: 40
Study 23095710 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 40